Equities researchers at StockNews.com assumed coverage on shares of Avinger (NASDAQ:AVGR – Get Free Report) in a note issued to investors on Saturday. The firm set a “hold” rating on the medical device company’s stock.
Separately, HC Wainwright reissued a “buy” rating and issued a $5.00 target price on shares of Avinger in a research report on Thursday, March 21st.
Check Out Our Latest Stock Report on AVGR
Avinger Trading Up 2.6 %
Avinger (NASDAQ:AVGR – Get Free Report) last announced its quarterly earnings results on Wednesday, May 15th. The medical device company reported ($2.49) EPS for the quarter, missing the consensus estimate of ($1.35) by ($1.14). The company had revenue of $1.86 million for the quarter, compared to analysts’ expectations of $2.36 million. On average, equities research analysts predict that Avinger will post -2.08 earnings per share for the current year.
Avinger Company Profile
Avinger, Inc, a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.
Further Reading
- Five stocks we like better than Avinger
- How to Buy Cheap Stocks Step by Step
- Top 3 Defense Stocks That Should Be on Your Radar
- Stock Market Sectors: What Are They and How Many Are There?
- Why This Banking Stock Might Be Nearing the Bottom of Its Cycle
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- MarketBeat Week in Review – 7/8 – 7/12
Receive News & Ratings for Avinger Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avinger and related companies with MarketBeat.com's FREE daily email newsletter.